Repare Therapeutics Inc. (RPTX) announced on Thursday that they have received a $40 million milestone payment from Roche. This payment was part of their agreement with Roche for the development and commercialization of camonsertib.
The milestone payment came into effect after the first patient was administered with camonsertib in Roche's Phase 2 TAPISTRY trial. TAPISTRY is a Phase 2 study aimed to assess the safety and efficiency of targeted therapies or immunotherapy in participants with solid tumors.
According to the agreement with Roche, Repare is eligible to receive up to $1.2 billion in potential milestone payments, in addition to royalties on global net product sales.
